ImmuPharma plc (LON:IMM – Get Free Report)’s share price rose 13.6% during trading on Thursday . The stock traded as high as GBX 14.45 ($0.19) and last traded at GBX 13.06 ($0.18). Approximately 24,707,008 shares changed hands during trading, an increase of 189% from the average daily volume of 8,537,366 shares. The stock had previously closed at GBX 11.50 ($0.15).
ImmuPharma Stock Performance
The firm has a market cap of £62.47 million, a P/E ratio of -1,404.49 and a beta of 1.53. The company has a 50-day moving average of GBX 4.28 and a 200 day moving average of GBX 3.27.
ImmuPharma (LON:IMM – Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 09/15 – 09/19
- How to Find Undervalued Stocks
- Tesla: 2 Reasons to Love Musk’s $1B Buy, 1 Reason to Be Bearish
- Profitably Trade Stocks at 52-Week Highs
- Azure Leads While AI Excitement Fuels Microsoft Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
